Calithera Drops Development Of Lead Candidate Telaglenastat

Interim Phase II Lung Cancer Data Underwhelming

 
• By Ayisha Sharma
  
Telaglenastat Was First Glutaminase Inhibitor In Clinic • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D